Cortex District member C2N Diagnostics is emerging as a leader in the biopharma sector, as it has recently secured a $10 million investment from life science companies under Samsung. JAMA recently published a study about C2N's blood test algorithm and found that the "result delivered a highly statistically significant accuracy of over 90%" when diagnosing Alzheimer's disease in primary care settings. Read more here via St. Louis Business Journal: https://lnkd.in/g-t6w-eX
